NZ708392A - Functionalized benzamide derivatives as antiviral agents against hbv infection - Google Patents

Functionalized benzamide derivatives as antiviral agents against hbv infection

Info

Publication number
NZ708392A
NZ708392A NZ708392A NZ70839213A NZ708392A NZ 708392 A NZ708392 A NZ 708392A NZ 708392 A NZ708392 A NZ 708392A NZ 70839213 A NZ70839213 A NZ 70839213A NZ 708392 A NZ708392 A NZ 708392A
Authority
NZ
New Zealand
Prior art keywords
benzamide derivatives
functionalized
antiviral agents
hbv infection
functionalized benzamide
Prior art date
Application number
NZ708392A
Other languages
English (en)
Inventor
Xiaodong Xu
Timothy M Block
Ju-Tao Guo
Yanming Du
Original Assignee
Baruch S Blumberg Inst
Univ Drexel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baruch S Blumberg Inst, Univ Drexel filed Critical Baruch S Blumberg Inst
Priority to NZ748966A priority Critical patent/NZ748966A/en
Publication of NZ708392A publication Critical patent/NZ708392A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/66—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/75—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
    • C07D321/02—Seven-membered rings
    • C07D321/10—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/72—Benzo[c]thiophenes; Hydrogenated benzo[c]thiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epidemiology (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pain & Pain Management (AREA)
NZ708392A 2012-12-06 2013-12-05 Functionalized benzamide derivatives as antiviral agents against hbv infection NZ708392A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ748966A NZ748966A (en) 2012-12-06 2013-12-05 Functionalized benzamide derivatives as antiviral agents against hbv infection

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261734184P 2012-12-06 2012-12-06
PCT/US2013/073319 WO2014089296A2 (en) 2012-12-06 2013-12-05 Functionalized benzamide derivatives as antiviral agents against hbv infection

Publications (1)

Publication Number Publication Date
NZ708392A true NZ708392A (en) 2020-05-29

Family

ID=50884140

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ708392A NZ708392A (en) 2012-12-06 2013-12-05 Functionalized benzamide derivatives as antiviral agents against hbv infection
NZ748966A NZ748966A (en) 2012-12-06 2013-12-05 Functionalized benzamide derivatives as antiviral agents against hbv infection

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ748966A NZ748966A (en) 2012-12-06 2013-12-05 Functionalized benzamide derivatives as antiviral agents against hbv infection

Country Status (13)

Country Link
US (2) US20150307443A1 (cg-RX-API-DMAC7.html)
EP (1) EP2928459A4 (cg-RX-API-DMAC7.html)
JP (2) JP6353460B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150090219A (cg-RX-API-DMAC7.html)
CN (2) CN104918612B (cg-RX-API-DMAC7.html)
AU (2) AU2013355220B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015013121A2 (cg-RX-API-DMAC7.html)
CA (1) CA2892606A1 (cg-RX-API-DMAC7.html)
IL (1) IL238930B (cg-RX-API-DMAC7.html)
NZ (2) NZ708392A (cg-RX-API-DMAC7.html)
PH (1) PH12015501276A1 (cg-RX-API-DMAC7.html)
SG (2) SG11201503997VA (cg-RX-API-DMAC7.html)
WO (1) WO2014089296A2 (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2896554C (en) 2012-12-27 2019-11-05 Drexel University Novel antiviral agents against hbv infection
DK3116316T3 (da) 2014-03-13 2019-08-19 Univ Indiana Res & Tech Corp Allosteriske modulatorer af hepatitis b-kerneprotein
EP3292120B1 (en) * 2015-05-04 2019-06-19 H. Hoffnabb-La Roche Ag Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of hbsag (hbv surface antigen) and hbv dna production for the treatment of hepatitis b virus infections
TW201720802A (zh) 2015-09-15 2017-06-16 艾森伯利生物科學公司 B型肝炎核心蛋白質調節劑
EP3500294A4 (en) 2016-08-22 2020-07-29 Arbutus Biopharma Corporation ANTI-PD-1 ANTIBODIES, OR THEIR FRAGMENTS, FOR THE TREATMENT OF HEPATITIS B
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
WO2018052967A1 (en) * 2016-09-13 2018-03-22 Arbutus Biopharma, Inc. Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same
WO2018053157A1 (en) 2016-09-15 2018-03-22 Assembly Biosciences, Inc. Hepatitis b core protein modulators
AU2017353986B2 (en) 2016-11-07 2021-08-19 Arbutus Biopharma Corporation Substituted pyridinone-containing tricyclic compounds, and methods using same
AU2018227811A1 (en) 2017-03-02 2019-09-19 Assembly Biosciences, Inc. Cyclic sulfamide compounds and methods of using same
EP3601216B1 (en) 2017-03-21 2023-10-25 Arbutus Biopharma Corporation Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same for the treatment of hepatitis b virus infection
AU2019223182B2 (en) 2018-02-26 2021-08-19 Gilead Sciences, Inc. Substituted pyrrolizine compounds as HBV replication inhibitors
CN112724037B (zh) * 2018-06-13 2022-03-11 浙江大学 一种羟苯水杨胺羟基化物、制备方法及其应用
TWI826492B (zh) 2018-07-27 2023-12-21 加拿大商愛彼特生物製藥公司 經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法
CA3117449A1 (en) 2018-10-22 2020-04-30 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
US20210395751A1 (en) 2018-10-31 2021-12-23 The University Of Sydney Compositions and methods for treating viral infections
TW202415643A (zh) 2018-12-12 2024-04-16 加拿大商愛彼特生物製藥公司 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法
SG11202112590WA (en) 2019-05-24 2021-12-30 Assembly Biosciences Inc Pharmaceutical compositions for the treatment of hbv
MX2022007738A (es) 2019-12-20 2022-07-19 Arbutus Biopharma Corp Procesos e intermedios sinteticos.
CN115916341A (zh) 2020-04-22 2023-04-04 组装生物科学股份有限公司 用于治疗hbv的吡唑甲酰胺化合物
AR121905A1 (es) 2020-04-22 2022-07-20 Assembly Biosciences Inc Compuestos de carboxamida heteroarilo de 5 miembros para el tratamiento del hbv
WO2021216661A1 (en) 2020-04-22 2021-10-28 Assembly Biosciences, Inc. Pyrazole carboxamide compounds for treatment of hbv
WO2021216660A1 (en) 2020-04-22 2021-10-28 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
US20210371388A1 (en) * 2020-05-12 2021-12-02 Baruch S. Blumberg Institute Bicyclic Carboxamide with Exocyclic Urea Derivatives as Antivirals for the Treatment of HBV Infection
TW202214574A (zh) * 2020-06-08 2022-04-16 加拿大商愛彼特生物製藥公司 經取代之(呔-1-基甲基)脲類、經取代之n-(呔-1-基甲基)醯胺類及其類似物
WO2023069544A1 (en) 2021-10-20 2023-04-27 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
WO2023069545A1 (en) 2021-10-20 2023-04-27 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
WO2023069547A1 (en) 2021-10-20 2023-04-27 Assembly Biosciences, Inc. 5-membered heteroaryl carboxamide compounds for treatment of hbv
WO2023164179A1 (en) 2022-02-25 2023-08-31 Assembly Biosciences, Inc. Benzothia(dia)zepine compounds for treatment of hbv and hdv
WO2023164183A1 (en) 2022-02-25 2023-08-31 Assembly Biosciences, Inc. Benzothia(dia)zepine compounds for treatment of hbv and hdv
WO2023164181A1 (en) 2022-02-25 2023-08-31 Assembly Biosciences, Inc. Benzothia(dia)zepine compounds for treatment of hbv and hdv
WO2023164186A1 (en) 2022-02-25 2023-08-31 Assembly Biosciences, Inc. Benzothia(dia)zepine compounds for treatment of hbv and hdv
JPWO2024128244A1 (cg-RX-API-DMAC7.html) 2022-12-14 2024-06-20
WO2025043094A1 (en) 2023-08-23 2025-02-27 Assembly Biosciences, Inc. Benzothia(dia)zepine compounds for treatment of hbv and hdv

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL108459A0 (en) * 1993-02-05 1994-04-12 Opjohn Company 4-Hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl [B] pyran-2-ones useful for treating infections due to hiv and other retroviruses
JPH06297860A (ja) * 1993-04-14 1994-10-25 New Oji Paper Co Ltd 感熱記録体
WO1999025327A2 (en) * 1997-11-14 1999-05-27 Warner-Lambert Company Small molecule intervention in hiv-1 replication
SI1037880T1 (en) * 1997-12-11 2004-10-31 Janssen Pharmaceutica N.V. Retinoic acid mimetic anilides
US6653309B1 (en) * 1999-04-26 2003-11-25 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme technical field of the invention
WO2002000613A2 (en) * 2000-06-27 2002-01-03 Axxima Pharmaceuticals Ag Inhibitors of hepatitis b virus infection
DE10109856A1 (de) * 2001-03-01 2002-09-05 Bayer Ag Arzneimittel gegen virale Erkrankungen
KR100863667B1 (ko) * 2002-09-11 2008-10-15 가부시끼가이샤 구레하 아민 화합물 및 그 용도
WO2004110352A2 (en) * 2003-05-16 2004-12-23 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
SE0401342D0 (sv) * 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds
WO2007047646A2 (en) * 2005-10-14 2007-04-26 Janssen Pharmaceutica, N.V. Substituted dihydro-isoindolones useful in treating kinase disorders
CN1951932B (zh) * 2005-10-20 2010-11-24 北京科莱博医药开发有限责任公司 [n-(3',4'亚甲二氧基)苯基乙基]甲酰胺基苯甲酸衍生物,它们的制备方法及其用途
UA116187C2 (uk) * 2005-12-13 2018-02-26 Інсайт Холдінгс Корпорейшн ГЕТЕРОАРИЛЗАМІЩЕНІ ПІРОЛО[2,3-b]ПІРИДИНИ Й ПІРОЛО[2,3-b]ПІРИМІДИНИ ЯК ІНГІБІТОРИ ЯНУС-КІНАЗИ
WO2007143557A2 (en) * 2006-06-02 2007-12-13 Brandeis University Compounds and methods for treating mammalian gastrointestinal parasitic infections
DE102006060598A1 (de) * 2006-12-21 2008-06-26 Merck Patent Gmbh Tetrahydrobenzoisoxazole
JP5746860B2 (ja) * 2007-04-09 2015-07-08 メチルジーン インコーポレイテッド ヒストンデアセチラーゼ阻害剤
CA2715960A1 (en) * 2007-12-27 2009-07-09 F. Hoffmann-La Roche Ag Insulin-degrading enzyme crystals
CN104163816A (zh) * 2008-12-03 2014-11-26 普雷西迪奥制药公司 Hcv ns5a的抑制剂
EP2377850A1 (en) * 2010-03-30 2011-10-19 Pharmeste S.r.l. TRPV1 vanilloid receptor antagonists with a bicyclic portion
WO2012058378A1 (en) * 2010-10-29 2012-05-03 Romark Laboratories L.C. Pharmaceutical compositions and methods of use of salicylanilides for treatment of hepatitis viruses
EP2688864A1 (en) * 2011-03-22 2014-01-29 Syngenta Participations AG Insecticidal compounds
US9616064B2 (en) * 2011-03-30 2017-04-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Rho kinase inhibitors and methods of use

Also Published As

Publication number Publication date
AU2018256602A1 (en) 2018-11-22
US20190092720A1 (en) 2019-03-28
SG11201503997VA (en) 2015-06-29
EP2928459A2 (en) 2015-10-14
IL238930B (en) 2020-06-30
CN104918612B (zh) 2019-10-25
IL238930A0 (en) 2015-07-30
EP2928459A4 (en) 2016-10-26
CN110642741A (zh) 2020-01-03
JP6353460B2 (ja) 2018-07-04
SG10201900695PA (en) 2019-02-27
KR20150090219A (ko) 2015-08-05
PH12015501276A1 (en) 2015-08-24
AU2013355220A1 (en) 2015-06-18
CN104918612A (zh) 2015-09-16
JP2018162272A (ja) 2018-10-18
BR112015013121A2 (pt) 2017-07-11
US20150307443A1 (en) 2015-10-29
JP2016506387A (ja) 2016-03-03
CA2892606A1 (en) 2014-06-12
NZ748966A (en) 2020-05-29
WO2014089296A3 (en) 2014-08-07
AU2013355220B2 (en) 2018-08-02
WO2014089296A2 (en) 2014-06-12

Similar Documents

Publication Publication Date Title
NZ708392A (en) Functionalized benzamide derivatives as antiviral agents against hbv infection
NZ703064A (en) Inhibitors of hepatitis c virus
PH12018550201A1 (en) Hepatitis b antiviral agents
PH12018550148A1 (en) Hepatitis b antiviral agents
MX359989B (es) Fármacos antivirales para el tratamiento de la infección por arenavirus.
WO2009123776A3 (en) Antiviral drugs for treatment of arenavirus infection
WO2017027350A3 (en) Rnai therapy for hepatitis b virus infection
IN2014MN01547A (cg-RX-API-DMAC7.html)
MX2012000959A (es) Inhibidores de los virus flaviviridae.
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.
NZ709260A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
MX2012008221A (es) Inhibidores de virus flaviviridae.
NZ703040A (en) Macrocyclic inhibitors of flaviviridae viruses
MX2012008211A (es) Inhibidores de virus flaviviridae.
PH12014502739A1 (en) Macrocyclic inhibitors of flaviviridae viruses
TN2013000421A1 (en) 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EA026667B9 (ru) Фармацевтическая композиция для лечения вируса гепатита с
IN2012DN01855A (cg-RX-API-DMAC7.html)
GEP201706698B (en) Inhibitors of influenza viruses replication
MX2010002278A (es) Farmacos antivirales para el tratamiento de una infeccion por arenavirus.
GEP20186938B (en) Indolizine derivatives as phoshoinositide 3-kinases inhibitors
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
PH12014500385A1 (en) Benzofuran compounds for the treatment of hepatitis c virus infections
MX2014014878A (es) Combinacion de agentes terapueticos para tratar infeccion por el virus de la hepatitis c (hcv).
IN2011CH03893A (cg-RX-API-DMAC7.html)

Legal Events

Date Code Title Description
PSEA Patent sealed
LAPS Patent lapsed